In a phase II clinical trial, Curalogic has shown that its grass product is well tolerated without up-dosing

Announcement no. 10/2007                                                        


To OMX the Nordic Exchange	                               Copenhagen, May 15th, 
2007                                                                            






In a phase II clinical trial, Curalogic has shown that its grass product is well
tolerated without up-dosing                                                     

Summary: Curalogic has concluded a Phase II clinical trial that explored the    
possibility of eliminating up-dosing (titration) at initiation of treatment. The
result shows that that the grass product is well-tolerated without up-dosing.   
This is important because it is easier for the patients to taker the same dose  
throughout the full treatment period. The market for Curalogic's grass product  
is large, as there are approximately 51 million people in Europe and 30 million 
people in the USA suffering from grass allergy.                                 

In the phase II clinical trial, GPE 02, which Curalogic has already reported on 
in May 2007, it was shown that high doses of the grass product were             
well-tolerated with up-dosing. As an extension to GPE 02, Curalogic has         
administered the grass product to a new group of patients (cohort B) and can now
report that a high dose of the grass product also is well tolerated without     
preceding up-dosing. This result is important because it is easier for the      
patients to administer the same dose of the product through the full treatment  
regime.                                                                         

Dr. Jörg Kleine-Tebbe of the Allergy & Asthma Center Westend, Berlin, Germany   
was the principal investigator in this trial. The trial was double-blinded,     
randomised, and placebo-controlled. In cohort B, 15 patients with moderate to   
severe grass pollen allergy, were treated daily for a week outside the grass    
pollen season with 32,000 BAU of microencapsulated grass pollen extract (10     
patients) or placebo (5 patients).  BAU is the biological potency of the product
defined relative to a FDA reference standard for grass pollen extract.          

The key results from the cohort B trial were:                                   
All patients completed the entire trial.                                        
No serious adverse events or severe adverse events were observed in the trial.  
32,000 BAU of the grass product was well-tolerated and all adverse events were  
mild.                                                                           

A comparison with the tolerability from the GPE 02 trial, indicate that at a    
dose level of 32,000 BAU, tolerability is similar with or without preceding     
up-dosing. Curalogic expect, based on the results from this trial, to be able to
omit up-dosing with the grass product in the coming EU phase III trial.         
Further, the results from this trial support the good tolerability of oral      
immunotherapy using Curalogic's formulation technology.                         


Curalogic's product for the treatment of grass allergy                          
The active ingredient of the micro-encapsulated grass product candidate is an   
extract of Timothy grass pollen (Phleum Pratense L.).                           

Curalogic's microcapsulated formulation has been used to administer grass pollen
extract in two clinical trials. The trials included a total of 93 patients with 
moderate to severe grass allergy who were dosed on a daily basis for 1 to 10    
weeks. The highest dose tested is 64,000 BAU, which is approximately 30 times   
higher than the maintenance dose with injection immunotherapy recommended in the
US. No treatment related serious adverse events or anaphylactic reactions were  
reported during the trials. The grass product was well-tolerated and the adverse
events were similar in nature as those observed for the ragweed product. The    
next step in development is an EU Phase III trial and Curalogic is discussing   
the conduct of this study with the company's clinical advisors.                 


Yours sincerely,                                                                

Curalogic A/S                                                                   


For additional information, please contact:                                     
Peter Moldt, President and CEO, 	Phone +45 33 11 41 01, mobile +45 26 25 04 22  
Helle Busck Fensvig, EVP and CFO, 	Phone +45 33 11 41 01, mobile +45 20 70 55 37


About Curalogic                                                                 
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic        
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the        
treatment of allergy. By combining the best of two worlds - the efficacy of     
immunotherapy combined with the safety and patient convenience of symptomatic   
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.  
Curalogic has a broad and mature pipeline with a product for treatment of       
ragweed allergy in Phase III, a product for treatment of grass allergy ready for
Phase III, a product for treatment of cat allergy in Phase II and a product for 
treatment of house dust mite allergy preparing for clinical trials.             




























This announcement contains forward-looking statements regarding the company's   
future financial development and performance and other statements which are not 
historical facts. Such statements are made on the basis of assumptions and      
expectations which, to the best of the company's knowledge, are reasonable at   
this time, but may prove to be erroneous in the future.